Antibody Therapeutics Patients First!

공지사항


번호 제목 작성자 작성일 조회
52   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine has presented as invited speaker at GBC 2018 on June 26-29, 2018   관리자   2018-08-06   2,835  
51   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited as a chairman of the session of the antibody therapeutics at BIOPLUS 2018 on September 6-9, 2018.   관리자   2018-08-06   8,642  
50   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a presentation as a speaker and panelist at AFOB SUMMER FORUM 2018   관리자   2018-08-06   2,661  
49   [공지사항]   관리자   2018-08-06   2,141  
48   [공지사항]   관리자   2018-08-06   2,111  
47   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is attending ASCO 2018.   관리자   2018-08-06   2,640  
46   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine and Dr. Sung Woo Kim, Head of Business Development are attending BIO 2018.   관리자   2018-08-06   2,485  
45   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at the company presentation session at BIO 2018.   관리자   2018-08-06   31,733  
44   PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme.   관리자   2018-08-06   38,461  
43   `` Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model`` is now indexed on PubMed.   관리자   2018-08-06   9,751